Singapore, June 25 -- A Korean molecular diagnostic company, Gencurix, Inc., has announced that they have received U.S. Food and Drug Administration (FDA)'s Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test.

It is the second RT-PCR test that Gencurix has launched following the first test assay, GenePro COVID-19 Detection Test released last March.

Key advantages of GenePro SARS-CoV-2 test include simultaneous monitoring of up to 384 samples which would allow high throughput screening of the novel coronavirus. With the FDA's EUA, Gencurix is now able to provide its COVID-19 detection tests the U.S. nationwide.

Gencurix's GenePro SARS-CoV-2 Test has the flexibility in the number of samples it can test simultaneously depend...